<< Back
Biologic therapy monitoring: IDKmonitor® Golimumab drug level ELISA
Article number:
K 9656
96 Tests
Incubation time:
1 h, 1 h, 10-20 min
10 µl
Serum, EDTA Plasma
4.15-225 ng/ml
Details (PDF)
To access these files, you need the Acrobat Reader
The success of a TNFalpha blocker therapy e. g. in patients with inflammatory bowel diseases is dependent on the choice of the appropriate drug, an effective dosage and, when indicated, the administration of immunosuppressive medication. For an optimal individual control of these parameters, Immundiagnostik now offers the following contract analyses of TNFalpha blocker drug levels:

IDKmonitor® -determination of TNFalpha blocker drug levels
  • Specific ELISA analysis of TNFalpha blocker: drug level of Infliximab (e.g. Remicade®), drug level of Adalimumab (e.g. Humira®) or drug level of Golimumab (e. g. Simponi®)
  • Drug level determination in serum and EDTA plasma
  • High analytic sensitivity
  • Regular monitoring of trough levels facilitates dosage adjustments and provides information about therapy failure

Contact for Immundiagnostik‘s IDKmonitor® TNFalpha blocker therapy contract analysis Jana Ruppert

Purchase Order Processing

Claudia Wandesleben / Gudrun Gutschalk
Phone: +49 6251 70190-175 /-177
Fax: +49 6251 70190-363
email: export@immundiagnostik.com

Contact Form Order Form